Alkermes to Participate in Upcoming Investor Conferences
Alkermes plc (Nasdaq: ALKS) has announced its participation in two major upcoming investor conferences in March 2025. The company will engage in webcast fireside chats at the TD Cowen 45th Annual Health Care Conference on March 5 at 9:50 a.m. ET and the Leerink Partners Global Healthcare Conference 2025 on March 12 at 11:20 a.m. ET.
The webcasts will be accessible through the Investors tab on Alkermes' website and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with a portfolio including treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations across Ireland, Massachusetts, and Ohio.
Alkermes plc (Nasdaq: ALKS) ha annunciato la sua partecipazione a due importanti conferenze per investitori che si terranno a marzo 2025. L'azienda parteciperà a chiacchierate in webcast durante il TD Cowen 45° Annual Health Care Conference il 5 marzo alle 9:50 a.m. ET e il Leerink Partners Global Healthcare Conference 2025 il 12 marzo alle 11:20 a.m. ET.
I webcast saranno accessibili tramite la sezione Investitori sul sito web di Alkermes e rimarranno archiviati per 14 giorni. Alkermes è un'azienda biopharmaceutica globale focalizzata sulle neuroscienze, con un portafoglio che include trattamenti per la dipendenza da alcol, la dipendenza da oppioidi, la schizofrenia e il disturbo bipolare di tipo I. L'azienda opera in Irlanda, Massachusetts e Ohio.
Alkermes plc (Nasdaq: ALKS) ha anunciado su participación en dos importantes conferencias para inversores que se llevarán a cabo en marzo de 2025. La compañía participará en charlas en webcast durante la 45ª Conferencia Anual de Salud de TD Cowen el 5 de marzo a las 9:50 a.m. ET y la Conferencia Global de Salud de Leerink Partners 2025 el 12 de marzo a las 11:20 a.m. ET.
Los webcasts estarán disponibles a través de la pestaña de Inversores en el sitio web de Alkermes y permanecerán archivados durante 14 días. Alkermes es una compañía biofarmacéutica global centrada en la neurociencia, con un portafolio que incluye tratamientos para la dependencia del alcohol, la dependencia de opioides, la esquizofrenia y el trastorno bipolar tipo I. La empresa tiene operaciones en Irlanda, Massachusetts y Ohio.
알켐스 plc (Nasdaq: ALKS)는 2025년 3월에 열리는 두 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다. 이 회사는 3월 5일 오전 9시 50분 ET에 TD Cowen 제45회 연례 건강 관리 회의와 3월 12일 오전 11시 20분 ET에 Leerink Partners 글로벌 건강 관리 회의 2025에서 웹캐스트 파이어사이드 채팅에 참여할 예정입니다.
웹캐스트는 알켐스 웹사이트의 투자자 탭을 통해 접근할 수 있으며, 14일 동안 아카이브로 남아 있습니다. 알켐스는 신경과학에 중점을 둔 글로벌 생물 제약 회사로, 알코올 의존증, 오피오이드 의존증, 조현병 및 양극성 장애 I형 치료제를 포함한 포트폴리오를 보유하고 있습니다. 이 회사는 아일랜드, 매사추세츠 및 오하이오에서 운영되고 있습니다.
Alkermes plc (Nasdaq: ALKS) a annoncé sa participation à deux grandes conférences pour investisseurs prévues en mars 2025. L'entreprise participera à des discussions en webcast lors de la 45e Conférence Annuelle sur la Santé de TD Cowen le 5 mars à 9h50 ET et de la Conférence Mondiale sur la Santé de Leerink Partners 2025 le 12 mars à 11h20 ET.
Les webcasts seront accessibles via l'onglet Investisseurs sur le site d'Alkermes et resteront archivés pendant 14 jours. Alkermes est une entreprise biopharmaceutique mondiale axée sur les neurosciences, avec un portefeuille comprenant des traitements pour la dépendance à l'alcool, la dépendance aux opioïdes, la schizophrénie et le trouble bipolaire de type I. L'entreprise opère en Irlande, dans le Massachusetts et dans l'Ohio.
Alkermes plc (Nasdaq: ALKS) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im März 2025 angekündigt. Das Unternehmen wird an Webcast-Gesprächen während der 45. jährlichen Gesundheitskonferenz von TD Cowen am 5. März um 9:50 Uhr ET und der Leerink Partners Global Healthcare Conference 2025 am 12. März um 11:20 Uhr ET teilnehmen.
Die Webcasts sind über den Investorenbereich auf der Website von Alkermes zugänglich und werden 14 Tage lang archiviert. Alkermes ist ein globales biopharmazeutisches Unternehmen, das sich auf Neurowissenschaften konzentriert und ein Portfolio mit Behandlungen für Alkoholabhängigkeit, Opioidabhängigkeit, Schizophrenie und bipolare Störung I umfasst. Das Unternehmen ist in Irland, Massachusetts und Ohio tätig.
- None.
- None.
TD Cowen 45th Annual Health Care Conference
Date/Time: Wednesday, March 5, 2025 at 9:50 a.m. ET (2:50 p.m. GMT)
Leerink Partners Global Healthcare Conference 2025
Date/Time: Wednesday, March 12, 2025 at 11:20 a.m. ET (3:20 p.m. GMT)
The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-upcoming-investor-conferences-302386193.html
SOURCE Alkermes plc
FAQ
When is Alkermes (ALKS) presenting at the TD Cowen Healthcare Conference in 2025?
How can investors access Alkermes (ALKS) conference webcasts in March 2025?
What therapeutic areas does Alkermes (ALKS) focus on in their product portfolio?
What upcoming conferences will Alkermes (ALKS) participate in during March 2025?
Where are Alkermes' (ALKS) main operational locations?
